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For personal use only. on . by guest www.bloodjournal.org From dependent cytotoxicity (R-CDC). We observed that incubation of Raji cells with rituximab leads to increased levels of ubiquitinated CD20. However, inhibition of the UPS was not associated with up-regulation of surface CD20 levels although it significantly increased its ubiquitination. Short-term (24h) incubation of Raji cells with 10 or 20 nM bortezomib did not change surface CD20 levels, but sensitized CD20 + lymphoma cells to R-CDC. Prolonged (48h) incubation with 20 nM bortezomib, or incubation with 50 nM bortezomib for 24h led to a significant decrease in surface CD20 levels as well as R-CDC. These effects were partly reversed by bafilomycin A1, an inhibitor of lysosomal/autophagosomal pathway of protein degradation. These studies indicate that CD20 levels are regulated by two proteolytic systems and that the use of proteasome inhibitors might be associated with unexpected negative influence on R-CDC.
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INTRODUCTION
Rituximab, a genetically engineered chimeric monoclonal antibody that specifically binds to CD20, represents a major therapeutic advance in the treatment of B-cell malignancies and some autoimmune diseases. Its mechanisms of antitumor action include induction of antibody-dependent cellular cytotoxicity (ADCC) [1] [2] , complement-dependent cytotoxicity (CDC) 1, [3] [4] , induction of apoptosis (after cross-linking) 5 , and possibly facilitation of adaptive immune response 6 .
Combination therapies with rituximab and systemic chemotherapy result in higher response rates and prolonged survival. However, most patients experience relapses and the efficacy of rituximab seems to decrease during the treatment [7] [8] [9] . The explanation for this therapeutic resistance is not completely elucidated. Possible mechanisms include downregulation of CD20 expression [10] [11] [12] , induction of complement regulatory proteins on the surface of malignant cells [13] [14] [15] , formation of blocking anti-chimeric antibodies 16 , or changes in membrane lipid composition [17] [18] . Therefore, novel treatment regimens in which rituximab is combined with therapeutics interfering with resistance mechanisms are needed.
The B-cell-specific surface marker CD20 was considered to be a stable target for monoclonal antibodies (mAb). However, this concept needs to be revisited in light of recent studies indicating that CD20 expression is regulated at both pre-transcriptional and posttranscriptional levels [19] [20] . For example, it is now widely recognized that surface CD20 is modulated by rituximab itself in a process referred to as shaving, which in vitro resembles trogocytosis, and is a process of plasma membrane exchange within immunological synapse that forms between tumor and FcγR-bearing cell [21] [22] [23] . Also, an increasing number of therapeutics have been reported to affect the amounts of surface CD20. These include cytokines such as GM-CSF and IL-4 as well as a number of approved or experimental therapeutics. For example, prednisolone 14 , bryostatin-1 20 , radiotherapy [24] [25] , and reactive oxygen species 25 were demonstrated to up-regulate CD20 levels in B cells or B-cell tumors.
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Little is known about the molecular mechanisms governing regulation of CD20 levels.
Elucidation of these mechanisms is of potential clinical relevance as biological effects of anti-CD20 mAb depend to a large extent on the density of surface CD20 expression 10, 15 and rituximab resistance is at least to some extent associated with lowered CD20 levels [28] [29] .
Recent studies indicate that CD20 is regulated by epigenetic mechanisms as 5-azacytidine that inhibits DNA methyltransferase can increase CD20 levels in primary B-cell lymphoma . It is unclear however, why incubation of rituximab-resistant cell lines with bortezomib, a proteasome inhibitor, led to increased expression of COOH-terminal region of the internal domain of CD20, but not the whole CD20 molecule 31 .
Here, we decided to address in more detail the influence of proteasome inhibitors on the CD20 levels as well as rituximab-mediated CDC and ADCC towards CD20-positive B-cell malignancies.
Materials and methods

Cell culture
Human Burkitt's lymphoma (Daudi, Raji, Ramos) and human follicular lymphoma (DoHH2) cell lines were purchased from ATCC (Manassas, VA). Cells were cultured in RPMI 1640
(Invitrogen, Co., Paisley, UK), supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 µg/ml streptomycin and 250 ng/ml amphotericin B (Invitrogen). Cells were cultured at 37°C in a fully humidified atmosphere of 5% CO 2 and were passaged every other day. Normal B cells from healthy volunteers or primary cells from patients with B-cell tumors 
Isolation of primary normal B cells from blood of healthy donors
The peripheral blood mononuclear cells were isolated from blood of healthy donors using Histopaque 1077. Briefly, blood (50 ml from each of donors) was diluted twice with PBS. Every 10 ml of diluted blood was slowly layered on the top of 3 ml of Histopaque 1077. After 30 min centrifugation (700 g, 25°C) white blood cell rings were isolated, washed twice with PBS and resuspended in RPMI at a concentration of 1x10 8 cells/ml. Isolation of B cells was performed using purple EasySep magnet and human CD19 positive selection kit (STEMCELL Technologies, Vancouver, BC). According to the manufacturer's protocol PBMC were incubated for 15 min with positive selection cocktail followed by 10-min incubation with magnetic nanoparticles. A total of four 5-min separations in the magnet were performed.
Reagents
Rituximab, a chimeric IgG1, was purchased from Roche. Bortezomib obtained from Millenium Pharmaceuticals (Cambrigde, MA) was dissolved in 0.9% NaCl. MG132, epoxomycin, PSI and tunicamycin were purchased from Calbiochem (San Diego, CA), and were dissolved in DMSO. Acridine orange (dissolved in PBS), bafilomycin A1 (dissolved in DMSO) and 3-methyladenine (3-MA) (dissolved in dH 2 O) were purchased from Sigma.
Recombinant HSP70 was purchased from Assay Designs, Ann Arbor, MI.
Cytotoxicity assay
Complement dependent cytotoxicity was determined by an assay with 3-[4,5-dimethylthiazol- 
Flow cytometry
The following fluorochrome-conjugated antibodies were used for flow cytometry studies:
FITC-conjugated anti-CD20 (clone B9E9 [HRC20]; Beckman Coulter), anti-CD55 (clone IA10, BD Pharmingen), anti-CD59 (clone p282, BD Pharmingen) and FITC-conjugated IgG1 (isotypic control, Beckman Coulter). The following unconjugated mAb were used: anti-CD21 (Gen Trak, Inc.), anti-CD45RA (clone L48, BD Biosciences), anti-CD46 (clone J4.48, Beckman Coulter), anti-CD54 (clone 84H10, Immunotech), anti-HLA-DR (clone L243, BD Biosciences), anti-C5b-9 (clone aE11, mAb reacting with neoepitope on poly C9 complement factor, DakoCytomation). Cells were analyzed on a FACSCalibur (Becton Dickinson) using Cell-Quest Pro software version 5.2 as described 17 .
Autophagy detection with acridine orange staining
Control and bortezomib-pretreated cells (0.5 x 10 6 ) suspended in 1 ml of PBS were stained with 1 µg/ml acridine orange for 15 min, then the cells were washed with PBS, resuspended in 0. For personal use only. on November 12, 2017. by guest www.bloodjournal.org From biotinylation. Afterwards, beads were spun at 16 000 g for 30 s and the supernatant was collected and used as a biotinylation and CD20 precipitation control (membrane fraction).
After five washings, gel-bound complexes were boiled in 2x Laemmli sample buffer that releases immunoprecipitated proteins from their binding with antibodies and protein G agarose beads and subsequently analyzed for CD20-ubiquitination with Western blotting using anti-CD20 mAb (Novocastra) and anti-ubiquitin antibody. Anti-ICAM1 and anti-tubulin antibodies (both from Santa Cruz) were used for detection of membrane and cytosolic proteins, respectively, in subcellular fractions.
Reverse transcription-PCR
RNA was isolated using Chomczynski's modified method. RT-PCR was performed with AMV reverse transcriptase (Promega, Madison, WI) according to the manufacturers protocol. PCR was performed using GoTaq Flexi DNA Polymerase (Promega) using pairs of primers indicated in table 1. Amplification products were analyzed by 1.5% agarose gel electrophoresis.
Statistical analysis
Data were calculated using Microsoft™ Excel 2007. Differences in in vitro cytotoxicity assays were analyzed for significance by Student's t test. Significance was defined as a two-sided p < 0.05. All the experiments using cell lines were performed independently at least three times.
Results
Rituximab binding increases the levels of ubiquitinated CD20
It was recently demonstrated that incubation of CD20 + B-cell tumors with rituximab leads to decreased surface levels of CD20 accompanied by induction of several components of the ubiquitin-proteasome system 31 . Therefore, Raji cells were incubated with 10 µg/ml rituximab for 24-72h to see whether it affects the levels and/or ubiquitination of CD20. Western blotting analysis was used to determine the total cellular levels of CD20 as the detection of surface CD20 with B9E9 antibodies used in flow cytometry is hampered by rituximab (data not shown). The levels of CD20 did not change in rituximab-incubated cells as detected by
Western blotting (Fig. 1A) . However, immunoprecipitation of CD20 followed by immunoblotting revealed that it is already ubiquitinated in control cells and this posttranslational modification of CD20 becomes further increased in rituximab-treated cells (Fig. 1B) . This observation fosters the possibility that the CD20 levels can be regulated by proteasomes.
Bortezomib modulates surface CD20 levels
In preliminary experiments the cytostatic/cytotoxic effects of bortezomib as well as other proteasome inhibitors were investigated to establish concentrations of these compounds that incubation with 50 nM bortezomib led to a significant drop in CD20 levels (Fig. 2B) . RT-PCR indicated only a slight decrease in CD20 mRNA levels after incubation of Raji cells with 20 nM bortezomib detected only after 48h (Fig. 2C) .
Incubation of Raji cells with bortezomib did not significantly affect surface levels of other B-cell surface molecules such as CD21, CD45RA, CD54 or HLA-DR ( Fig. 2D and Supplemental Figure 5 ).
Bortezomib-mediated modulation of CD20 levels was also observed in three consecutive primary tumor cultures obtained from patients with CD20 + tumors. In two of these there was an up-regulation of CD20 after 24h of incubation with bortezomib, and downregulation at 48h. In the third patient's cells there was no significant change in CD20 levels at 24h, but a significant drop at 48h (Fig. 2E) .
In order to see whether incubation of Raji cells with bortezomib might lead to extracellular release of CD20 to the culture supernatant an immunoprecipitation assay was done with anti-CD20 mAb. These experiments revealed that there is no soluble CD20 in controls nor in groups incubated with bortezomib ( Figure 2F ).
Bortezomib and other proteasome inhibitors affect rituximab-mediated CDC but not ADCC
To investigate whether changes in CD20 levels correlate with R-CDC Raji cell were preincubated with proteasome inhibitor, collected, rinsed with PBS and exposed to rituximab (1, 10 and 100 µg/ml) in the presence of 10% human AB serum for 1h. Incubation of Raji cells with bortezomib at 10 and 20 nM concentrations for 12 and 24h significantly potentiated R-CDC, but a 24h incubation with 50 nM or prolonged (48h) incubation with 10 or 20 nM bortezomib concentrations significantly decreased R-CDC (Fig. 3A) . Bortezomib-mediated modulation of R-CDC was also observed when 50% serum was used for 1, 4 or 24h (Supplemental Figure 6 ). Changes in sensitivity to R-CDC in bortezomib-treated cells
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Incubation of Raji cells with bortezomib did not affect the sensitivity of tumor cells to ADCC (Fig. 3C) .
Similar changes in R-CDC sensitivity were observed in other CD20-positive B-cell tumors (Daudi, DoHH2, Ramos) -a short incubation time (24h) was associated with increased sensitivity, while a longer incubation time (48h) resulted in decreased R-CDC (Fig.   4A ). Also other proteasome inhibitors (epoxomycin, MG132 and PSI) sensitized Raji cells to R-CDC when used for a 24h incubation time, and impaired R-CDC when used for 48h ( A 24h pre-incubation with bortezomib increased, while a 48h pre-incubation decreased R-CDC in three primary cell cultures of CD20 + B cell tumors freshly obtained from patients ( Fig. 4C) . Bortezomib was used at low (1, 5 or 10 nM) concentrations in these experiments that were not associated with significant cytostatic/cytotoxic effects (not shown).
Bortezomib regulates complement regulatory protein levels
An intriguing observation that short-term (up to 24h) pre-incubation of Raji cells with bortezomib or other proteasome inhibitors sensitizes these cells to R-CDC without accompanying rise in CD20 levels indicates that other mechanisms might contribute to this effect. One potential mechanism might result from modulation of surface complement regulatory proteins levels. Indeed, flow cytometry (Fig. 5A ) revealed that bortezomib strongly affects surface levels of CD46, CD55 as well as CD59. This effect likely results from transcriptional regulation as RT-PCR analyses revealed a drop in mRNA levels for all three complement regulatory proteins (Fig. 5B ).
For
Bortezomib increases ubiquitination of surface CD20 molecules
To investigate the influence of proteasome inhibition on the levels as well as ubiquitination of CD20, controls or cells incubated with bortezomib were lysed and CD20 was immunoprecipitated. Immunoprecipitation of CD20 followed by Western blotting analysis revealed that a 24h incubation of Raji cells with a high (50 nM) bortezomib concentration or for prolonged (48h) time with 20 nM bortezomib led to decreased levels of CD20 in total cellular lysates (Fig. 6A, top) . Decreased levels of CD20 in Raji cells incubated with a high (50 nM) bortezomib concentration or for prolonged time (48h) with a lower (20 nM) bortezomib concentration were accompanied by strongly increased levels of its ubiquitination (Fig. 6A, bottom) . Immunoprecipitation provides the information on the whole pool of CD20 including intracellular and plasma membrane-associated molecules. To check whether changes in ubiquitination include membrane CD20 molecules surface proteins were performed. Electrophoresis of the immunoprecipitates followed by immunoblotting with anti-CD20 mAb revealed that bortezomib decreases CD20 levels in the plasma membrane and that membrane CD20 is ubiquitinated (Fig. 6B, top) . Western blotting of the EZ-link ® sulfo-NHS-biotin-precipitated material confirmed that it contains membrane (ICAM-1), but not cytosolic (tubulin) proteins (Fig. 6B, middle) . The fraction of the lysate that was not precipitated contained cytosolic, but not membrane proteins (Fig. 6B, bottom) . Preliminary experiments revealed that incubation of normal B cells (isolated from peripheral blood of 5 consecutive healthy volunteers with anti-CD19 magnetic beads) with bortezomib at 1 and 10 nM concentration for 24 and 48h leads to increased CD20 ubiquitination. In contrast to tumor cells, the levels of CD20 in normal B cells were up-regulated (Supplemental Figure 7) .
Bortezomib induces lysosomal/autophagic degradation of CD20
The unexpected finding of decreased levels of CD20 and increased levels of its ubiquitination in cells incubated with bortezomib indicates that inhibition of proteasome activity might lead to secondary activation of another proteolytic system that participates in the degradation of CD20. Previous studies indicate that there might be an extensive cross-talk between ubiquitin-proteasome system and autophagic pathway of protein degradation 32 . Indeed, we have observed that incubation of Raji cells with bortezomib leads to processing of LC3-I to its phosphatidylethanolamine-conjugated form, LC3-II, which participates in the autophagic sequestration process (Fig. 7A,B) , and to increased staining with acridine orange, an lysosomal/autophagosomal marker ( Fig. 7C and 8A ), indicating induction of autophagy (see also a Supplemental Figure 8 ).
Bafilomycin A1, a vacuolar type H( Immunoprecipitation of CD20 followed by Western blotting analysis revealed that bafilomycin A1 partly restored CD20 levels in whole Raji cells lysates (Fig. 8B ) as well as in the membrane fraction (Fig. 8C) . Also, flow cytometry analyses revealed that both bafilomycin A1 (Fig. 8D ) and 3-MA (Supplemental Figure 7) reverse bortezomib-induced decrease in surface CD20 levels. Partial restoration of surface CD20 expression with bafilomycin A1 correlated with partial restoration of R-CDC in bortezomib-treated Raji cells (Fig. 8E) .
Discussion
The results presented in this article report for the first time that CD20 is ubiquitinated in tumor cells and that rituximab binding increases ubiquitination of this molecule (Fig. 1B) . The significance of this process remains to be elucidated. Numerous integral membrane proteins, For personal use only. on November 12, 2017. by guest www.bloodjournal.org From including receptors, channels, transporters and enzymes undergo posttranslational modification by the covalent attachment of ubiquitin. This process leads to targeting of the modified proteins for proteasomal degradation or serves as a molecular recognition signal in membrane trafficking or regulation of endocytosis 34 . Circumstantial evidence indicates that ubiquitination might also be involved in targeting of membrane proteins for degradation in lysosomes 35 . Despite increased ubiquitination, we have not observed modulation of CD20 levels by rituximab (Fig. 1A) . However, inhibition of proteasome activity resulted in bi-modal regulation of CD20 levels. Bortezomib used at 10 or 20 nM for up to 24h did not affect surface CD20 levels ( Fig. 2A and D) , but increased the amount of CD20 in total cellular lysates (Fig. 2B ). This observation indicates that the cellular pool of CD20 is to some extent regulated by the ubiquitin-proteasome pathway. Incubation of Raji cells with 50 nM bortezomib for 24h or with 20 nM bortezomib for 48h resulted in an unexpected drop in surface CD20 levels ( Fig. 2A and D) . Pandey et al., have shown that there is a cross-talk between the ubiquitin-proteasome and autophagy pathways 32 . Upregulation of autophagy seems to be a rescue mechanism that reduces toxicity induced by proteasome inhibition by facilitating the clearance of proteins that would otherwise accumulate in cells with impaired proteasome activity. Indeed, induction of autophagy in Raji cells incubated with bortezomib was observed (Fig. 7) . Concomitant inhibition of proteasome activity and vacuolar type H( + )-ATPase, which participates in acidification of lysosomes led to a partial restoration of CD20 levels. These observations indicate that both ubiquitin-proteasome as well as lysosomal/autophagosomal pathways participate in the degradation of CD20.
Although in normal B cells bortezomib also modulated CD20 ubiquitination levels there was an increase rather than decrease in CD20 levels at 48h (Supplemental Figure 7 ).
These observations indicate that the consequences of CD20 ubiquitination might be different in normal as compared to transformed cells. Elucidation of the mechanisms and potential significance of these disparate outcomes requires further studies.
Changes in surface CD20 levels induced by proteasome inhibitors roughly correlated with the ability to trigger R-CDC but not ADCC. These observations are to some extent at Blots were sequentially probed (after stripping) with anti-tubulin and anti-CD20 antibodies.
(B) Raji cells were seeded into the 25 cm 2 bottles at a concentration of 5 x 10 5 cells/10 ml.
The cells were exposed to 10 μ g/ml rituximab for 24h, 48h or 72h, after which protein lysates were prepared. CD20 antigen was immunoprecipitated from samples with protein G bead slurry and subjected to Western blot analysis. Blots were sequentially probed (after stripping)
with anti-ubiquitin and anti-CD20 antibodies. 
